ACTR-II Antibody (F-12): sc-390977

ACTR-II Antibody (F-12) is a mouse monoclonal IgG2a kappa light chain antibody that detects ACTR-II protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Anti-ACTR-II antibody (F-12) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. ACTR-II protein plays a crucial role in the transforming growth factor β (TGF-β) signaling pathway, which is essential for regulating various cellular processes such as proliferation, differentiation, and apoptosis. ACTR-II serves as a type II receptor that forms a heteromeric complex with type I receptors, facilitating the binding of ligands like activin. This interaction is vital for proper functioning of the signaling cascade, influencing gene expression and cellular responses. Expression of ACTR-II is particularly high in the brain, where ACTR-II is implicated in neurodevelopment and modulation of neuronal functions. Understanding ACTR-II dynamics and interactions with other proteins in the TGF-β superfamily is important for elucidating ACTR-II′s role in health and disease, making ACTR-II monoclonal antibody (F-12) a valuable tool for researchers studying these complex biological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ACTR-II Antibody (F-12) References:

1. A short loop on the ALK-2 and ALK-4 activin receptors regulates signaling specificity but cannot account for all their effects on early Xenopus development.  |  Armes, NA., et al. 1999. J Biol Chem. 274: 7929-35. PMID: 10075688
2. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.  |  Morvan, F., et al. 2017. Proc Natl Acad Sci U S A. 114: 12448-12453. PMID: 29109273
3. Chemotropic signaling by BMP7 requires selective interaction at a key residue in ActRIIA.  |  Perron, JC., et al. 2019. Biol Open. 8: PMID: 31208997
4. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension.  |  Yung, LM., et al. 2020. Sci Transl Med. 12: PMID: 32404506
5. Activin A impairs ActRIIA+ neutrophil recruitment into infected skin of mice.  |  Qi, Y., et al. 2021. iScience. 24: 102080. PMID: 33604525
6. Upregulation of Actin-Related Protein 2 (ACTR2) Exacerbated the Malignancy of Diffuse Large B-Cell Lymphoma through Activating Wnt Signaling.  |  Chen, D. and Jiang, L. 2022. Comput Math Methods Med. 2022: 9351921. PMID: 36570337
7. Screening for the presence of aberrantly expressed ACTR2 in osteosarcoma and analyzing its mechanism of action through an online database.  |  Yi, M., et al. 2024. Am J Cancer Res. 14: 4065-4081. PMID: 39267681
8. Cloning and characterization of a human type II receptor for bone morphogenetic proteins.  |  Rosenzweig, BL., et al. 1995. Proc Natl Acad Sci U S A. 92: 7632-6. PMID: 7644468
9. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin.  |  Cárcamo, J., et al. 1994. Mol Cell Biol. 14: 3810-21. PMID: 8196624
10. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors.  |  Attisano, L., et al. 1993. Cell. 75: 671-80. PMID: 8242742
11. The ALK-2 and ALK-4 activin receptors transduce distinct mesoderm-inducing signals during early Xenopus development but do not co-operate to establish thresholds.  |  Armes, NA. and Smith, JC. 1997. Development. 124: 3797-804. PMID: 9367435
12. Bone morphogenetic proteins and their receptors: potential functions in the brain.  |  Ebendal, T., et al. 1998. J Neurosci Res. 51: 139-46. PMID: 9469567

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-ACTR-II Antibody (F-12) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-ACTR-II Antibody (F-12) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

ACTR-II Antibody (F-12) Specifications

Alternate Product Name: ACVR2A

Product Clone Name: F-12

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 396-460

Epitope Target: ACTR-IIA

Epitope Species: human

Product Reactivity/Detection: ACTR-IIA and ACTR-IIB

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for ACTR-II Antibody (F-12): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred ACTR-IIB antibody is ACTR-IIB Antibody (G-7): sc-376593.